Toronto-based healthcare company StageZero reports Q1 2024 revenue decline in cancer testing & treatment to $0.523M, while net loss improves to $0.386M.
StageZero Life Sciences, a Toronto-based healthcare company, reported Q1 2024 financial results with a decline in revenue, generating $0.523M in cancer testing & treatment revenue (down from $0.778M in Q1 2023). Net loss improved to $0.386M (from $1.812M in Q1 2023). The company advanced conversations with new partners, completed Richmond lab reorganization, and focused on US/Europe expansion, multiple hospital studies, and COC Protocol 2.0 launch.
May 17, 2024
5 Articles